Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies-Reference-Cited by-同舟云学术

Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies

Published:2018-03-26 Issue:4 Volume:24 Page:604-610
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Rusen L.¹,Kavakli K.²^ORCID,Korth-Bradley J.³^ORCID,Huard F.⁴,Rendo P.³,Fuiman J.³,Baumann J. A.³,Smith L.³,Alvey C.⁵,Rupon J.³^ORCID

Affiliation:

1. Prof. Dr. C. T. Nicolau National Institute for Transfusional Haematology; Bucharest Romania

2. Department of Haematology; Ege University Children's Hospital; Izmir Turkey

3. Global Product Development; Pfizer Inc.; Collegeville PA USA

4. Global Product Development; Pfizer Inc.; Paris France

5. Pfizer Inc.; Groton CT USA

Funder

Pfizer

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13466/fullpdf

Reference19 articles.

1. An improved manufacturing process for Xyntha/ReFacto AF;Kelley;Haemophilia,2010

2. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII;Recht;Haemophilia,2009

3. Xyntha [package insert] Philadelphia, PA Wyeth Pharmaceuticals (Pfizer Inc) 2015

4. European Medicines Agency Summary of Product Characteristics: ReFacto AF http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000232/WC500049008.pdf

5. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings;Parra Lopez;Thromb Haemost,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A;Blood Reviews;2023-12

2. Identification of iron metabolism-related predictive markers of endometriosis and endometriosis-relevant ovarian cancer;Medicine;2023-04-14

3. BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial;Thrombosis and Haemostasis;2023-01

4. Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?;Blood Advances;2022-12-02

5. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial;Haemophilia;2019-12-09